Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : Amlodipine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Study Phase : Phase I
Recipient : Brillian Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Amlodipine Freeze-Dried Powder for Oral Solution 5 mg
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 11, 2023
Lead Product(s) : Amlodipine,Inapplicable
Therapeutic Area : Cardiology/Vascular Diseases
Highest Development Status : Phase I
Recipient : Brillian Pharma
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Nefopam Hydrochloride,Paracetamol
Therapeutic Area : Undisclosed
Study Phase : Phase I
Recipient : Unither Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 22, 2021
Lead Product(s) : Nefopam Hydrochloride,Paracetamol
Therapeutic Area : Undisclosed
Highest Development Status : Phase I
Recipient : Unither Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Methotrexate,Inapplicable
Therapeutic Area : Dermatology
Study Phase : Phase I
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
BE Study in Patients - Methotrexate Tablets
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 21, 2016
Lead Product(s) : Methotrexate,Inapplicable
Therapeutic Area : Dermatology
Highest Development Status : Phase I
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Imatinib Mesylate,Inapplicable
Therapeutic Area : Oncology
Study Phase : Phase II/ Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
April 03, 2014
Lead Product(s) : Imatinib Mesylate,Inapplicable
Therapeutic Area : Oncology
Highest Development Status : Phase II/ Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Asenapine Maleate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II/ Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Bioequivalence Fasting Study in Patients
Details : Undisclosed
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 27, 2014
Lead Product(s) : Asenapine Maleate,Inapplicable
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II/ Phase III
Recipient : Amneal Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable